Form 4: Artivion Executive Reports Stock Transactions

Artivion's EVP, COO, CFO & Treasurer, Lance A. Berry, reported sales of common stock to cover tax obligations and an acquisition of restricted stock.

Summary

• Lance A. Berry, EVP, COO, CFO & Treasurer of Artivion, Inc. (AORT), reported several transactions involving the company's common stock.
• On February 23, 2026, 4,981 shares of common stock were sold at $37.588 per share. This sale was non-discretionary, executed to cover tax withholding obligations upon the vesting of performance stock units.
• On February 24, 2026, an additional 4,485 shares of common stock were sold at $35.693 per share. This was also a non-discretionary "sell to cover" transaction for tax withholding obligations related to the vesting of restricted stock units.
• On February 24, 2026, Berry acquired 37,482 shares of restricted stock at a price of $0. These shares will vest 33 1/3% per year starting on the first anniversary of the grant date, under the Equity and Cash Incentive Plan.
• Following these transactions, Berry's direct beneficial ownership of common stock increased to 181,447 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. The sales were non-discretionary for tax purposes, and the acquisition represents routine equity compensation, neither indicating a significant positive nor negative shift in company fundamentals or insider sentiment.

Positives

• The acquisition of 37,482 shares of restricted stock at a $0 price indicates a grant of equity compensation, aligning management's interests with shareholders.

Negatives

• Sales of 9,466 shares of common stock occurred, though these were non-discretionary "sell to cover" transactions for tax obligations.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule for the newly acquired restricted stock.

Industry Context

StockSavvy.ai notes that insider transaction reports like Form 4 are routine disclosures. While sales by executives can sometimes signal concerns, these specific transactions are explicitly identified as non-discretionary 'sell to cover' for tax purposes, which is a common practice for equity compensation vesting and typically does not reflect a change in management's outlook on the company's prospects. The grant of restricted stock units is a standard component of executive compensation packages in the medical device industry, aiming to align executive incentives with long-term shareholder value.

Stakeholder Impact

• Shareholders: The increase in direct beneficial ownership of common stock by a key executive, even with the 'sell to cover' transactions, generally aligns management's long-term interests with shareholder value.
• Employees: The equity compensation plan (Equity and Cash Incentive Plan) is a standard mechanism for incentivizing key personnel.

Next Steps

• The acquired restricted stock shares will vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the Equity and Cash Incentive Plan.

Key Dates

Recommendation

The transactions reported are primarily non-discretionary 'sell to cover' sales for tax obligations and a routine grant of restricted stock. These types of insider filings typically do not signal a change in the company's fundamental outlook or warrant a change in investment strategy. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Artivion, AORT, Lance A. Berry, SEC Form 4, Insider Trading, Stock Transaction, Restricted Stock Units, Performance Stock Units, Equity Compensation, Sell to Cover